Magnetic resonance imaging to evaluate NASHA/Dx gel (Zuidex) for stress urinary incontinence.
The Zuidex system for the treatment of stress urinary incontinence consists of non-animal stabilised hyaluronic acid/dextranomer (NASHA/Dx) gel and a precision guide, the Implacer. Whether the Implacer accurately deposits NASHA/Dx gel in the desired location within the urethral wall was investigated by magnetic resonance imaging (MRI), performed at a mean of 35 days post-treatment. Three or more deposits were observed in 11 of 16 patients (68.8%), with 39 of the 50 deposits clearly located within the urethral wall, as intended. Fourteen of 16 patients (87.5%) demonstrated improvement in their incontinence at 3 months, sustained at 12 months in 13 patients. No significant correlations between total implant volume and improvements in incontinence were observed at 3 months (p > or = 0.16) and 12 months (p > or = 0.30). In conclusion, accurate placement of NASHA/Dx gel into the desired location within the urethral wall was achieved in the majority of cases using the Implacer device, without endoscopic guidance.
Fianu-Jonasson
A
A
Karolinska University Hospital, Huddinge, Stockholm, Sweden. aino.fianu-jonasson@karolinska.se
Edwall
L
L
Wiberg
M Kristoffersen
MK
D000328:Adult; D000368:Aged; D003911:Dextrans / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005782:Gels; D006801:Humans; D006820:Hyaluronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D016896:Treatment Outcome; D014550:Urinary Incontinence, Stress / Q000175:diagnosis / Q000188:drug therapy*
D003911:Dextrans; D005782:Gels; C496587:NASHA-Dx copolymer; D006820:Hyaluronic Acid